Results 21 to 30 of about 472,072 (313)
Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis
Background Ceramide plays pathogenic roles in nonalcoholic fatty liver disease (NAFLD) via multiple mechanisms, and as such inhibition of ceramide de novo synthesis in the liver may be of therapeutically beneficial in patients with NAFLD.
Rui-Xu Yang +11 more
doaj +1 more source
Adipokines and redox signaling: impact on fatty liver disease. [PDF]
Adipokines (adipose tissue cytokines) are polypeptide factors secreted by adipose tissue in a highly regulated manner. The 'classical' adipokines (leptin, adiponectin, and resistin) are expressed only by adipocytes, but other adipokines have been shown ...
Marra, Fabio. +2 more
core +1 more source
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes [PDF]
Background/aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is categorized into three subtypes: overweight/obese (OW), lean/normal weight with metabolic abnormalities, and diabetes mellitus (DM).
임태섭, 김승업, 김자경
core +1 more source
Non-alcoholic fatty liver disease (NAFLD) is characterized by the abnormal buildup of lipids in the liver tissue. Non-alcoholic fatty liver (NAFL) may progress to non-alcoholic steatohepatitis.
Zhixian Zhu +4 more
doaj +1 more source
Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease [PDF]
The polymorphism, KLF6-IVS1-27A, in the Krüppel-like factor 6 (KLF6) transcription factor gene enhances its splicing into antagonistic isoforms and is associated with delayed histological progression of nonalcoholic fatty liver disease (NAFLD).
Gastaldelli, Amalia +80 more
core +1 more source
Non-alcoholic steatohepatitis (NASH) is an epidemic metabolic disease with limited therapeutic strategies. Cumulative data support the pivotal role of gut microbiota in NASH.
Da Zhou +6 more
doaj +1 more source
Fatty liver disease: A gutsy way to prevent disease progression A treatment for non-alcoholic fatty liver disease that incorporates a metabolite found in the gut could prevent progression to a more serious liver condition. Drugs that enhance the activity
Da Zhou +8 more
doaj +1 more source
Background:Non-alcoholic fatty liver disease (NAFLD) is a global health problem affecting more than a quarter of the entire adult population. Both monocytes and high-density lipoprotein cholesterol (HDL-C) were found to participate in the progression of ...
Liping Wang +8 more
doaj +1 more source
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease : a systematic review [PDF]
Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world. There is a strong association of NAFLD with insulin resistance and, hence, insulin sensitisers have been tried.
C Clar +21 more
core +1 more source
Metabolism of Fatty Livers [PDF]
EARLIER work on the metabolism of fatty livers by Ennor1 showed that the oxygen consumption and the acetoacetic acid production of liver slices from guinea pigs poisoned with carbon tetrachloride is considerably in excess of normal. Since adenosinetriphosphate is essential for the oxidation of fatty acids2, it was considered of interest to determine a ...
A H, ENNOR, L A, STOCKEN
openaire +2 more sources

